# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

## Reason for visit

New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests. **S**

## Historical basis

- Ida B. Wells was born enslaved on July 16, 1862, in Holly Springs, Mississippi, during the Civil War. **D**
- In the yellow fever epidemic of 1878, when she was 16, both her parents and an infant brother died; she left school and took on the care of her surviving younger siblings, teaching to support them. **D**
- She was an investigative journalist and editor who documented lynching in the United States, notably in A Red Record (1895), and campaigned against it for the rest of her life; she was also a suffragist and civil rights leader. **D**
- On June 27, 1895, she married the Chicago attorney Ferdinand L. Barnett, kept her own name alongside his, and settled in Chicago; they had four children. **D**
- She signed the call for the 1909 conference that led to the National Association for the Advancement of Colored People and is considered one of its founders, though she was left off the list of its founding committee and later drew away from it. **D**
- In 1930 she ran, unsuccessfully, for the Illinois State Senate. **D**
- She began writing her autobiography in her last years; it was published after her death as Crusade for Justice: The Autobiography of Ida B. Wells, edited by her youngest daughter, Alfreda M. Duster. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normal. **S**
- She wants to keep working and finish her memoir. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- No historical medical events recorded.

## Procedures and immunizations

- 2026-01-05 to 2026-01-05: Twelve-lead electrocardiogram **S**


## Family history

- father: Died in the yellow fever epidemic when she was 16 **D** (CLM-0002)
- mother: Died in the yellow fever epidemic when she was 16 **D** (CLM-0002)
- brother: An infant brother died in the same yellow fever epidemic **D** (CLM-0002)

## Measurements

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Glucose (fasting): 94 mg/dL; Creatinine: 1.42 mg/dL (high); eGFR, creatinine (CKD-EPI 2021, race-free): 40 mL/min/1.73 m² (low); Cystatin C: 1.68 mg/L (high); eGFR, creatinine and cystatin C (CKD-EPI 2021, race-free): 38 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Hemoglobin A1c: 5.6%; Hemoglobin: 11.2 g/dL (low); Ferritin: 168 ng/mL; Transferrin saturation: 24%; Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 84 pg/mL (high); 25-hydroxyvitamin D: 17 ng/mL (low); Total cholesterol: 214 mg/dL (high); LDL cholesterol: 136 mg/dL (high); HDL cholesterol: 52 mg/dL; Triglycerides: 128 mg/dL; TSH: 1.9 mIU/L; PHQ-9: 4. All results are synthetic.

BP 164/94 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 70.4 kg; BMI 28.6 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, precise and questioning; asked for copies of every result; mood steady; PHQ-9 score 4. Functional status: Independent in all activities and instrumental activities of daily living; walks to meetings and the newspaper office, slowed by knee aching and by tiredness this winter. Physical examination is intentionally limited. **S**

## Assessment

1. Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established; status draft. **S**
2. Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm; status draft. **S**

## Plan

- Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counseling. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtain. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021) **S**
- Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weeks. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dye. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baseline. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (J Am Soc Nephrol 2021)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), New England Journal of Medicine (Inker LA, et al.)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
